EGFR and Skin rash: Skin rash was the most common (64.00% in the combination group and 70.15% in the EGFR-TKI monotherapy group) (p = 0.804), followed by elevated liver enzymes (62.00% in the combination group and 50.74% in the EGFR-TKI monotherapy group, p = 0.228).